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Colorectal cancer (CRC) is one of the major causes of mortality and morbidity, and is
the third most common cancer in men and the second most common cancer in women
worldwide.The incidence of CRC shows considerable variation among racially or ethnically
defined populations in multiracial/ethnic countries. The tumorigenesis of CRC is either
because of the chromosomal instability (CIN) or microsatellite instability (MIN) or involv-
ing various proto-oncogenes, tumor-suppressor genes, and also epigenetic changes in the
DNA. In this review I have focused on the mutations and polymorphisms of various impor-
tant genes of the CIN and MIN pathways which have been implicated in the development
of CRC.
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INTRODUCTION
Colorectal cancer (CRC) defined as the cancerous growths in the
colon, rectum and appendix is also referred to as colon cancer or
large bowel cancer. It is a commonly diagnosed cancer in both men
and women and represents the third most common form of cancer
and the second leading cause of cancer-related death in the western
world (Center et al., 2009). Sporadic CRC constitutes about 75%
of the patients, with no apparent evidence of having inherited the
disorder; while as the patients having a family history of CRC con-
stitutes the remaining 25% which suggests a genetic contribution,
common exposures among family members, or a combination
of both (National cancer Institute, 20081). In the countries like
Western Europe, North America, and Australia CRC has the high
incidence rates among the western world populations while as the
lowest rates of CRC are found in the sub-Saharan Africa, South
America and Asia, but are increasing in countries adopting western
life-style and dietary habits (Vainio and Miller, 2003).
Colorectal tumors present with a broad spectrum of neoplasms,
ranging from benign growths to invasive cancer, and are predom-
inantly epithelial-derived tumors (i.e., adenomas or adenocarci-
nomas). Pathologists have classified the lesions into three groups:
non-neoplastic polyps, neoplastic polyps (adenomatous polyps,
adenomas), and cancers (Zauber et al., 2002; O’Brien et al., 2004).
TYPES
Depending upon the genetics and the etiology of the disease, CRC
is usually categorized into three specific types: sporadic, inherited,
or familial.
Sporadic colorectal carcinomas
Sporadic carcinomas devoid of any familial or inherited predispo-
sition, accounts for approximately 70% of CRC. Sporadic cancer
1http://www.cancer.gov/cancertopics/pdq/genetics/colorectal/healthprofessional/
allpages
is common in persons older than 50 years of age, probably as
a result of dietary and environmental factors as well as normal
aging. Fewer than 10% of patients have an inherited predisposition
to colon cancer.
Inherited colorectal carcinomas
They include those in which colonic polyps are a major manifesta-
tion of disease and those in which they are not. The nonpolyposis
predominant syndromes include hereditary nonpolyposis CRC
(HNPCC) (Lynch syndrome I) and the cancer family syndrome
(Lynch syndrome II). Although uncommon, these syndromes
provide insight into the biology of all types of CRC.
Familial colorectal carcinomas
The third and least understood pattern of CRC development is
known as familial CRC. In affected families, CRC develops too
frequently to be considered sporadic but not in a pattern consis-
tent with an inherited syndrome. Up to 25% of all cases of CRC
may fall into this category (Paula and Harold, 2002).
CLASSIFICATION AND GRADING
The most common colon cancer cell type is adenocarcinoma
which accounts for 95% of cases. Other, rarer types include lym-
phoma and squamous cell carcinoma. Cancers on the right side
(ascending colon and cecum) tend to be exophytic, that is, the
tumor grows outward from one location in the bowel wall. Left-
sided tumors tend to be circumferential, and can obstruct the
bowel much like a napkin ring.
Two classification systems are being used for the staging of the
CRC-Dukes classification and TNM (Tumors/Nodes/Metastases)
system. Dukes’ classification, first proposed by Dukes (1932), iden-
tifies the stages as: (A) Tumor confined to the intestinal wall;
(B) Tumor invading through the intestinal wall; (C) With lymph
node(s) involvement; and (D) With distant metastasis, which is the
commonest in use still (Table 1). There has been a gradual move
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from using Dukes’s classification to using the TNM classification
system as this is thought to lead to a more accurate, independent
description of the primary tumors and its spread (Hardy et al.,
2001).
RISK FACTORS
A number of risk factors have been identified which increase the
person’s risk of developing CRC. The most important of these are
given in a Box 1, as has been identified by Mayo foundation.
GENETIC BACKGROUND
The majority of CRCs develop from benign pre-neoplastic lesions:
the adenomatous polyps or adenomas. A multistep model of car-
cinogenesis for the development of colorectal cancer have been
given by Vogelstein which describes the progression if a benign
adenoma to a malignant carcinoma through a series of well-
defined histological stages (Vogelstein et al., 1988), this is known as
the adenoma-carcinoma sequence model. This model describes an
accumulation of genetic events, each conferring a selective growth
Box 1 Various risk factors affecting the predisposition to colorectal cancer
Mayo Foundation for Medical Education and Research has indentified some of the factors the may increase the risk of colorectal cancer
which are summarized below:
Age: Although there is no defined age bar at which colorectal cancer can occur but persons older than 50 are at a higher risk of developing
colorectal cancer than younger people.
Gender: In developed countries, both men and women are affected equally while as in developing countries the men have been found to
be affected more than their women counterparts.
Ethnic Background/Race: African-Americans have a greater risk of colorectal cancer than do people of other races. Jews of Eastern
European descent (Ashkenazi Jews) may have a higher rate of colon cancer.
Inflammatory intestinal conditions: A person who has a history of Chrohn’s Disease and Inflammatory Bowel Disease has an increased
chance of developing colorectal cancer.
A Family history or personal of colorectal cancer or colon polyps: A person is more likely to develop colorectal cancer if anyone of
his/her parents; siblings or child is having the disease. If more than one family member has colon cancer or rectal cancer, the risk is even
greater. So is the case with person who has had colon cancer or adenomatous polyps.
Low-fiber, high-fat diet: A diet made up mostly of foods that are high in fat, especially from animal sources, can increase the risk of col-
orectal cancer. Colorectal cancer may be associated with a diet low in fiber and high in calories also. Some studies have found an increased
risk of colorectal cancer in people who eat diets high in red meat and processed meats.
A sedentary lifestyle: People who are not active have a higher risk of colorectal cancer. Smoking/Alcohol: Recent studies show that smokers
are 30% to 40% more likely than nonsmokers to die of colorectal cancer. Heavy use of alcohol has also been linked to colorectal cancer.
Diabetes: People with diabetes and insulin resistance may have an increased risk of colon cancer.
Obesity: People who are obese have an increased risk of colon cancer and an increased risk of dying of colorectal cancer when compared
with people considered normal weight.
Inherited syndromes that increase colon cancer risk: A person who has a specific inherited gene syndrome (such as Familial Adeno-
matous Polyposis (FAP) or Hereditary Non-Polyposis Colon Cancer (HNPCC) is at increased risk for developing colorectal cancer. Genetic
syndromes passed through generations of the family can increase the risk of colorectal cancer.
Radiation therapy for cancer: Radiation therapy directed at the abdomen to treat previous cancers may increase the risk of colorectal
cancer.
Table 1 | Staging and survival of colorectal cancers.
Duke’s staging TNM staging Description Survival (%)
Stage 0 Carcinoma in situ
A Stage I No nodal involvement, no metastases, tumor invades submucosa (T1, No, Mo); tumor
invades muscularis propria (T2, No, Mo)
90–100
B Stage II No nodal involvement, no metastases, tumor invades subserosa (T3, No, Mo); tumor
invades other organs (T4, No, Mo)
75–85
C Stage III Regional lymph nodes involved (any T, N1, Mo) 30–40
D Stage IV Distant metastases <5
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Box 2 Symptoms in patients suffering from colorectal cancer
The following symptoms may indicate colorectal cancer
• A change in bowel habits
• Diarrhea or constipation
• Feeling that the bowel does not empty completely
• Vomiting
• Blood in the stool
• Abdominal discomfort (gas, bloating, cramps)
• Weight loss of no known reasons
• Constant tiredness
• Unexplained anemia
Box 3 Diagnostic tests recommended for colorectal cancer
detection
Approved screening and diagnostic tools include:
• Fecal Occult Blood Test (FOBT)
• Flexible Sigmoidoscopy
• Double Contrast Barium Enema (DCBE)
• Colonoscopy
• DNA-based Stool Test and Virtual Colonoscopy
advantage to an affected colorectal cell. These genetic changes ulti-
mately result in uninhibited cell growth, proliferation, and clonal
tumor development. The additive and cumulative effect of these
somatic mutations has been shown to be the cause of sporadic
colorectal cancer.
The salient features of the Vogelstein’s model of CRC carcino-
genesis for sporadic cancers, can be conclusively drawn as: 1)
the mutational activation of oncogenes and/or the inactivation
of tumor suppressor genes results in colorectal carcinogenesis; 2)
at least four or five genes of a cell must undergo somatic muta-
tions so as to get malignantly transformed; 3) the characteristics
of the tumor is dependent upon the accumulation of multiple
genetic mutations rather than the sequence of mutations of the
genes involved; and 4) the features of the tumorigenic process of
colorectal cancer also apply to other solid tumors, such as breast,
stomach and pancreatic cancer.
Two major mechanisms of genomic instability have been iden-
tified that give rise to colorectal carcinoma development and
progression: chromosomal instability (CIN) and microsatellite
instability (MIN).
CHROMOSOMAL INSTABILITY
It is associated with the series of genetic changes that occur ini-
tially in some cases by loss of one allele at a chromosomal locus
(loss of heterozygosity) and may imply the presence of a tumor-
suppressor gene at that site. Loss of both alleles at a given locus
(homozygous deletion) is an even stronger indicator of the exis-
tence of a tumor-suppressor gene. Loss of heterozygosity occurs
clonally in both the adenoma-carcinoma sequence and ulcerative
colitis associated neoplasia. Many of these loci are already associ-
ated with one or more known candidate tumor-suppressor genes.
These include 3p21 (β-Catenin gene), 5q21 (APC gene), 9p (p16
and p15 genes), 13q (retinoblastoma gene), 17p (p53 gene), 17q
(BRCA1 gene), 18q (DCC and SMAD4 genes), and less frequently
16q (E-cadherin gene) (Esteller et al., 2001; Conlin et al., 2005;
Hsieh et al., 2005). FAP represents the hereditary syndrome dealing
with APC gene mutation (Fearon and Vogelstein, 1990).
MICROSATELLITE INSTABILITY
It comprises length alterations of oligonucleotide repeat sequences
that occur somatically in human tumors. Mutations in DNA mis-
match repair (MMR) genes result in a failure to repair errors that
occur during DNA replication in repetitive sequences [microsatel-
lites (MSI)], resulting in an accumulation of frameshift mutations
in genes that contain MSI. This failure leads to MIN type of
tumor and is the hallmark of HNPCC (Boland et al., 1998).
MIN is also found in 12–15% of sporadic CRCs. MIN tumors are
more frequently right-sided and poorly differentiated, and more
often display unusual histological type (mucinous), and marked
peri-tumoral and intra-tumoral lymphocytic infiltration (Dolcetti
et al., 1999; Benatti et al., 2005). Microsatellite instability also
occurs in patients with ulcerative colitis and is fairly common
in premalignant (dysplastic) and malignant lesions (21 and 19%,
respectively) (Kerr et al., 2001).
According to the Vogelstein’s model of CRC carcinogenesis the
etiology of CRC is multifactorial, and is likely to involve the actions
of genes at multiple levels of the carcinogenesis trail. Various genes
which have been implicated in the pathogenesis of CRC include
p53, p16, p14, APC, β-catenin, E-cadherin, Transforming Growth
Factor (TGF)-β, SMADs, MLH1, MSH2, MSH6, PMS2, AXIN,
STK11, PTEN, DCC, and KRAS (Sayar and Banerjee, 2007).
MOLECULAR MUTATIONS
The mutations whether point or gross mutations in a number of
tumor suppressor or oncogenes have been implicated in the devel-
opment of colorectal cancer in every corner and every population
of the world. A number of important genes whose mutations have
been ascertained to be present in the colorectal cancer have been
discussed in brief as below.
TP53
The TP53 gene is located on the short (p) arm of chromosome 17,
and 17p deletions are found in 6–25% of colonic adenomas and
in as many as 75% of colonic carcinomas (Baker et al., 1989). The
TP53 gene encodes a protein, which maintains genomic integrity
by inducing cell cycle arrest and apoptosis when DNA is damaged
(Levine et al., 1991). Mutations in TP53 gene occur in almost half
of all CRCs, proposed as a late event in the transition of an ade-
noma to carcinoma (Harris and Hollstein, 1993). The mutations
in p53 are thought to cause an increase in the half life of the pro-
tein and also often associated with overexpression in the nucleus,
in one view (Remvikos et al., 1990). Also, most of the mutations
in TP53 gene occur in exons 5–8, in highly preserved regions, and
in the three main structural domains of the p53 protein (L2, L3,
and loop-sheet-helix) (Borrensen-Dale et al., 1998). These muta-
tions cause the synthesis of a stable protein that loses the ability to
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bind DNA and to cause the activation of target genes (Soussi and
Beroud, 2001).
KRAS
KRAS gene located at 12p12 consists of six exons, spread over
35 kb of genomic DNA, alternative RNA splicing reveals two dif-
ferent transcripts of 5.5 and 3.8 kb. Ras proteins small monomeric
proteins of 189 amino acids with a molecular weight of 21 Kd
(Watzinger and Lion, 1999). These function as small GTPases
that cycle between inactive guanosine diphosphate (GDP)-bound
and active guanosine triphosphate (GTP)-bound conformations
(Ras–GDP and Ras–GTP, respectively) (Boguski and McCormick,
1993; Donovan et al., 2002). The human ras family consists of
three proto-oncogenes,Harvey (H)-,Kirsten (K)-, and N-ras, all of
which possess an intrinsic GTPase activity, implicated in the regu-
lation of their activity. RAS proteins control multiple pathways in
a tissue-specific manner, affecting cell growth, differentiation, and
apoptosis (Khosrave-far and Der, 1994). Specific mutations in the
RAS genes lead to the formation of constitutively active proteins,
which trigger the transduction of proliferative and/or differentia-
tive signals, even in the absence of extracellular stimuli (Fearon
and Vogelstein, 1990; Schubbert et al., 2007).
Human cancers frequently express mutant Ras proteins, termed
“oncogenic Ras.” Activating ras mutations can be found in human
malignancies with an overall frequency of 15–20% (Schubbert
et al., 2007). Activating mutations in the KRAS proto-oncogene
gene are involved in 25–60% of CRCs (Vogelstein et al., 1988;
Fearon and Vogelstein, 1990). The activating oncogenic mutations,
in particular of KRAS are found mostly (90%) in codons 12 and
13, but may also affect codon 61 (Fearon, 1994; Bazan et al., 2002).
The most frequently observed are the G>A, G>T, and G>C
transversions (Brink et al., 2005; Schubbert et al., 2007).
BRAF
BRAF gene is located at 7q34 in between NDUFB2 and MRPS33
genes. It is composed of 18 exons spanning in a region of 190 Kbp.
Its mRNA has 2478 bp. Braf protein consists of 766 amino acid
residues having MW of 85 Kd. TheBRAF gene is a proto-oncogene
that belongs to the Serine/Threonine Kinase Family. It is also
a member of the RAF Subfamily together with the ARAF and
RAF1 genes. Braf protein contains three highly conserved domains
RBD (Ras binding domain), CRD (Cysteine-rich domain), and KD
(Kinase domain). Within the kinase domain there lies two other
specific domains – one glycine motif (G-loop) in exon 11 and
other activation segment (AS) in exon 15 (Domingo and Schwartz,
2004).
BRAF presents somatic mutations in different sort of tumors,
predominantly in malignant melanoma, sporadic colorectal
tumors showing MMR defects in MSI, low-grade ovarian serous
carcinoma and thyroid papillary cancer. About 80% of these muta-
tions correspond to the hotspot transversion mutation T1799A
that causes the amino acidic substitution V600E (Davies et al.,
2002) The other 20% accounts for a wide variable range of mis-
sense mutations and all of them reside in the glycines of the G-loop
in the exon 11 or in the AS in exon 15 near the V600. The muta-
tion V600E confers transformant activity to the cells because it
mimics the phosphorylation of T599 and/or S602 in the AS and
so Braf rests constitutively active in a RAS independent manner
(Wan et al., 2004).
APC
APC is a classical tumor-suppressor gene located on 5q21 con-
taining 21 exons. APC transcript is 9.0 kb in length and the
most common isoform of Apc protein contains 2843 amino acids
with molecular weight of 310 kD. The Apc protein consists of an
oligomerization domain, armadillo region in the N-terminus, a
number of 15- and 20-amino acid repeats in the central portion,
and a C-terminus that contains a basic domain and binding sites
for EB1 and the human disk large (HDLG) protein. Although being
an integral part of the Wnt-signaling mechanism, it also plays
a role in cell–cell adhesion, stability of microtubular cytoskele-
ton, cell cycle regulation, and possibly apoptosis (Fearnhead et al.,
2001).
The APC gene product indirectly regulates transcription of
a number of critical cell proliferation genes, through its inter-
action with the transcription factor β-catenin. Apc binding to
β-catenin leads to ubiquitin-mediated beta catenin destruction;
loss of Apc function increases transcription of beta catenin tar-
gets. These targets include cyclin D, C-myc, ephrins, and caspases.
Apc also interacts with numerous actin and microtubule associ-
ated proteins. Apc itself stabilizes microtubules. Homozygous Apc
truncation has been shown to affect chromosome attachment in
cultured cells. Roles for Apc in cell migration have been demon-
strated in vitro and in mouse models (Hamelin, 1998; Polakis,
2000; Tirnauer, 2005).
In addition to the mutational inactivation, hypermethylation of
the gene promoter is the other important mechanism associated
with gene silencing (Chen et al., 2005). In many tumors the hyper-
methylation of CpG islands in gene promoters has been found to
be a frequent epigenetic change in cancers, and is usually associated
with the loss of transcription of APC (Esteller et al., 2000; Rowan
et al., 2000; Tsuchiya et al., 2000; Virmani et al., 2001; Esteller and
Herman, 2002; Kang et al., 2003; Lind et al., 2004; Zare et al., 2009).
Hypermethylation of the APC gene promoters has been reported
to be present in about 20–48 per cent of human CRCs (Hiltunen
et al., 1997; Esteller et al., 2000; Arnold et al., 2004; Lind et al.,
2004).
β-Catenin
β-Catenin is located at 3p22-p21.3 and encompasses 23.2 kb of
DNA containing 16 exons with mRNA transcript about 2343 bp
long coding 781 amino acid residue protein of 92 kD mol-
ecular weight. β-Catenin protein contains a phosphorylation
site by the serine-threonine glycogen synthase kinase-3β (GSK-
3β), an α-Catenin binding site, 13 armadillo repeats, and a
transactivating domain (from N-terminus to C-terminus). β-
Catenin is assumed to transactivate mostly unknown target genes,
which may stimulate cell proliferation (acts as an oncogene)
or inhibit apoptosis. The β-Catenin level in the cell is regu-
lated by its association with the adenomatous polyposis coli
(APC) tumor-suppressor protein, axin, and GSK-3β. Phosphory-
lation of b-catenin by the APC-axin-GSK-3β complex leads to its
degradation by the ubiquitin-proteasome system (Debuire et al.,
2002).
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β-Catenin is mutated in up to 10% of all sporadic colorec-
tal carcinoma by point mutations or in frame deletions of the
serine and threonine residues that are phosphorylated by GSK-
3β (Polakis, 2000). These mutations result in stabilization of β-
Catenin and activation ofWNT -signaling. Mutations in β-Catenin
occur in exclusivity to APC aberrations as both molecules are the
components of the same pathway (Behrens, 2005).
SMAD4
SMAD4 gene – also known as MADH4, DPC4 & JIP, is located
on the long arm (q) of chromosome 18 at band 21.1. The gene
encompasses 49.5 kb of DNA with 13 exons, out of which first two
exons do not code for any amino acid and hence constitute 5′-
UTR of the SMAD4 gene. SMAD4 mRNA transcript constitutes
3220 nucleotides (Saffroy et al., 2004). The protein of SMAD4
gene – Smad4 belongs to the Darfwin family of proteins which
harbors two conserved amino- and carboxyl-terminal domains
known as MH1 and MH2, respectively. Smad4 in the basal state
is found mostly as a homo-oligomer, most likely a trimer. It
is ubiquitously expressed within the human body. Smad4 is an
intracellular mediator of TGF-β family and activin type 1 recep-
tor. Smad4 mediate TGF-β signaling to regulate cell growth and
differentiation. TGF-β stimulation leads to phosphorylation and
activation of Smad2 and Smad3, which form complexes with
Smad4 that accumulate in the nucleus and regulate transcrip-
tion of target genes. By interacting with DNA-binding proteins,
Smad complexes then positively or negatively regulate the tran-
scription of target genes (Attisano and Wrana, 2000; Massagué
et al., 2000; Wrana, 2000; Attisano and Lee-Hoeflich, 2001; Shi,
2001).
The role of Smad4 gene as an important tumor-suppressor gene
came out by the novel study of the allelotype loss in pancreatic ade-
nocarcinoma (Shi, 2001). The tissue restriction of alterations in
DPC4, as in many other tumor-suppressor genes, emphasizes the
complexity of rate-limiting checkpoints in human tumorigenesis
(Schutte et al., 1996).
Smad4 was proposed to be a tumor-suppressor gene that may
function to disrupt TGF-β signaling. Mutant Smad4 proteins,
identified in human carcinomas, were found to be impaired in
their ability to regulate gene transcription. Most of Smad4 gene
mutations in human cancer are missense, nonsense, and frameshift
mutations at the mad homology 2 region (MH2) which interfere
with the homo-oligomer formation of Smad4 protein and hetero-
oligomer formation between Smad4 and Smad2 proteins, resulting
in disruption of TGF-β signaling (Shi, 2001; Woodford-Richens
et al., 2001; Roth et al., 2003).
AXIN
Axis inhibition protein (AXIN1) and its homolog AXIN2 (also
known as conductin) are tumor-suppressor genes and their
proteins act as master scaffold ones. AXIN1 is located on
16p13.3 while as AXIN2 is located 17q24.1 (Atlas.org). Axin
has plieotrophic effect on various signaling pathways. One of
its key functions is to negatively regulate the activity of the
WNT pathway by enhancing formation of the β-Catenin destruc-
tion complex. The Wnt/Wingless biological signaling pathway
plays an important role in both embryonic development and
tumorigenesis (Hong-Tao et al., 2007). The genomic region con-
taining the AXIN1/2 genes shows loss of heterozygosity and re-
arrangements in a variety of cancers. In addition somatic point
mutations and deletions have been identified in CRC, hepato-
cellular carcinomas, ovarian endometrioid adenocarcinomas, and
hepatoblastomas. Many of these mutations/deletions result in
translation of truncated proteins that are likely to be functionally
inactive (Lammi et al., 2004).
SINGLE-NUCLEOTIDE POLYMORPHISMS
The human genome contains a massive amount of genetic varia-
tion, such as the insertion/deletion of one or more nucleotides, the
copy-number variations (CNVs) that can involve DNA sequences
of a few kilobases up to millions of bases, and single-nucleotide
polymorphisms (SNPs), which are the substitution of a single-
nucleotide along the DNA (Ionita-Laza et al., 2009; Savas and
Liu, 2009). SNPs are the most common form of genetic variation.
There are>10 million SNPs estimated to be in the human genome
(Miller et al., 2005).
These days several molecular and epidemiological studies are
focusing on the role of SNP’s in modulating the risk of various
cancer and quite a number of studies have implicated various
gene polymorphisms in affecting the risk of cancer in almost all
the populations around the world.
TP53 polymorphism
In TP53 gene several polymorphisms have been identified both
in non-coding and coding regions (Murphy, 2006; Bojesen and
Nordestgaard, 2008; Costa et al., 2008; Whibley et al., 2009). Most
of these polymorphisms are SNPs affecting a single base. Within
the coding regions of TP53, only two important polymorphisms
are present which alter the amino acid sequence of their products
(Pietsch et al., 2006), these are located at codon 47 and codon 72
in exon 4. Codon 72 (Arg72Pro) – a frequent functional SNP that
leads to an arginine-proline amino acid change has been reported
by many authors (Thomas et al., 1999; Dumont et al., 2003).
Dumont et al., reported that the Arg72 allele, if in homozygous, has
an apoptosis-inducing ability 15-fold higher than does the Pro72
allele. According to Leu et al. (2004), this high apoptosis-inducing
ability of the Arg72 allele is in part due to its mitochondrial loca-
tion which makes it possible for TP53 to have a direct interaction
with pro-apoptotic BAK protein. Studies on this SNP function
were the basis for testing its impact on the risk and progression
of tumors, where the less apoptotic allele Pro72 was associated
with increased risk for development of tumors (Marin et al., 2000;
Ignaszak-Szczepaniak et al., 2006; Toyama et al., 2007). Codon 47
(Pro47Ser) – second most common polymorphism in TP53 that
leads to change of Proline with Serine was first identified by Felley-
Bosco et al. (1993). The Ser47 polymorphic variant is very rare,
with an allele frequency under 5% in populations of African ori-
gin (Murphy, 2006; Pietsch et al., 2006; Whibley et al., 2009). In a
pioneer study by Li et al. (2005), 106, it was found that the serine
47 polymorphic variant, which replaces the proline residue – nec-
essary for recognition by proline-directed kinases, is a markedly
poorer substrate for phosphorylation. Codon 47 encodes proline
(CCG) in wild-type p53, but in a small subset of individuals it can
encode serine (TCG).
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NQO1 polymorphism
NQO1 is located on chromosome 16q22, is 20 kb in length and
has 6 exons and 5 introns. NQO1 is a flavoprotein which func-
tions as a homodimer. The physiological dimer has one catalytic
site per monomer. Each monomer consists of 273 amino acids.
NQO1 is expressed in human epithelial and endothelial tissues
and at high levels throughout many human solid tumors. NQO1
is a mainly cytosolic enzyme although it has also been localized
in smaller amounts to mitochondria, endoplasmic reticulum and
nucleus (Ross, 2004; Chao et al., 2006). The enzyme is gener-
ally considered as a detoxification enzyme because of its ability to
reduce reactive quinones and quinone-imines to less reactive and
less toxic hydroquinones by its unique ability to use either NADH
or NADPH as reducing cofactors (Siegel et al., 2004). Because of its
reducing capabilityNQO1prevents the generation of semiquinone
free radicals and reactive oxygen species with its unique property
of transferring two electrons at a time to quinone, thus protecting
cells from oxidative damage (Chen et al., 1999; Winski et al., 2002).
CYP2E polymorphism
Cytochrome P450 2E1 (CYP2E1) gene is located on 10q26.3. It
is 18,754 bp long consisting of nine exons and eight introns,
which encodes a 493 amino acid protein. CYP2E1 belongs to the
cytochrome P450 superfamily (Wang et al., 2010). It is a nat-
ural ethanol-inducible enzyme that is of great interest due to
its role in the metabolism and bioactivation of many low mol-
ecular weight compounds, including ethanol, acetone, drugs like
acetaminophen, isoniazid, chlorzoxazone, and fluorinated anes-
thetics and many procarcinogens like benzene, N-nitrosoamines,
vinyl chloride, and styrene (Guengerich et al., 1991; Kharasch and
Thummel, 1993; Ulusoy et al., 2007; Zhou et al., 2010). CYP2E1
gene contains six restriction fragment length polymorphisms, of
these are the two important – RsaI polymorphism (CYP2E1∗5B;
C-1054T substitution) and the 96-bp insertion in its 5′-flanking
region have drawn much interest (Morita et al., 2008; Wang et al.,
2010; Zhou et al., 2010). RsaI polymorphism has been shown to
affect its transcription level. The variant type of this polymorphic
site can enhance the transcription and increase the level of CYP2E1
enzymatic activity in vitro (Hayashi et al., 1991). The variant allele
of the 96-bp insertion polymorphism was shown to express greater
transcriptional activity (Nomura et al., 2003).
MTHFR polymorphism
The MTHFR gene, located on 1p36.22, encompasses 19.3 kb
of DNA and is composed of 11 exons. The gene codes for a
74.6-kD protein of 656 amino acids (Saffroy et al., 2005). It is a
cytosolic enzyme that catalyzes the conversion of 5,10-methylene
tetrahydrofolate (THF) to 5-methylTHF, a cosubstrate for homo-
cysteine remethylation to methionine with subsequent production
of S-adenosyl methionine (SAM), the universal methyl donor
in humans, required for DNA methylation. The methylation of
homocysteine is catalyzed by the enzyme methionine synthase,
which requires the cofactor vitamin B12. MTHFR is also linked to
the production of dTMP via thymidylate synthase and to purine
synthesis and, therefore, plays a role in the provision of nucleotides
essential for DNA synthesis (Wagner, 1995). Thus, any defect in
the MTHFR gene will be reflected in a defect in the methylation
pattern of DNA as well as in its synthesis. Two common functional
polymorphisms have been defined in the MTHFR gene – one
is C677T and other A1298C. MTHFR C677T polymorphism is
the most important one regulating the function of this enzyme.
This polymorphism results in an alanine-to-valine substitution at
codon 222 of the protein (Frosst et al., 1995). This polymorphism
has a profound effect on the MTHFR protein, not only does it
decrease the thermal stability of this enzyme but also reduces its
activity (Cicek et al., 2004). Individuals with the variant Val/Val
genotype (TT) have no more than 30% of normal enzyme activ-
ity, and heterozygotes (CT) have 65% of normal enzyme activity
(Frosst et al., 1995; Kono and Chen, 2005). This substitution also
results in lower levels of 5-methyltetrahydrofolate, an accumu-
lation of 5,10-methylenetetrahydrofolate and increased plasma
homocysteine levels (Frosst et al., 1995; Ma et al., 1997; Bagley
and Selhub, 1998).
CONCLUSION
However, there is an unresolved debate among the geneticists
and molecular oncologists as to whether which of the two
pathways – CIN and MIN initiates and predisposes an individual
to the development of colorectal cancer. Still it is not clear which
of the two is the first event in the carcinogenesis. However, as per se
it is regarded that CIN is the earlier event in the tumorigenesis and
subsequently tumor progression. In addition there is the question
of the epigenetic silencing of the various CIN and MIN pathway
genes also which occurs exclusive or in addition to the mutations
of the genes thus adding a second dimension of complexity in the
molecular mechanism of the tumor development.
Also molecular biologist are fighting to double their efforts
to define and characterize various metabolic pathways associ-
ated with DNA structure and function like DNA methylation and
chromatin modification, changes in the patterns of mRNA and
noncoding RNA expression, and the consequent effect on the cor-
responding protein expression and posttranslational modification
which surely are the variables affecting the CRC tumorigenesis.
So, there are more than one pathway for the tumor to undergo
tumorigenesis and hence it is important for the molecular oncol-
ogist to obtain data about age, sex, tumor site, ethinicity, diet and
gut flora when investigating genetic and epigenetic risk factors for
CRC to understand the complex interactions among dietary and
environmental agents.
REFERENCES
Arnold, C. N., Goel, A., Niedzwiecki,
D., and Dowell, J. M. (2004). APC
promoter hypermethylation con-
tributes to the loss of APC expression
in colorectal cancers with allelic loss
on 5q. Cancer Biol. Ther. 3, 960–964.
Attisano, L., and Lee-Hoeflich,
S. T. (2001). The Smads.
Genome Biol. 2,
3010.1–3010.8.
Attisano, L., and Wrana, J. L. (2000).
Smads as transcriptional co-
modulators. Curr. Opin. Cell Biol.
12, 235–243.
Bagley, P. J., and Selhub, J. A.
(1998). common mutation in
the methylenetetrahydrofolate
reductase gene is associated with
an accumulation of formylated
tetrahydrofolates in red blood cells.
Proc. Natl. Acad. Sci. U.S.A. 95,
13217–13220.
Baker, S. K., Fearon, E. R., Nigro, J. M.,
Hamilton, S. R., Preisinger,A. C., Jes-
sup, J. M.,et al. (1989). Chromosome
17 deletions and p53 gene mutations
in colorectal carcinoma. Science 244,
217–221.
Bazan, V., Migliavacca, M., Zanna, I.,
Tubiolo, C., Grassi, N., Latteri, M.
A., et al. (2002). Specific codon 13
K-ras mutations are predictive of
clinical outcome in colorectal can-
cer patients, whereas codon 12 K-
ras mutations are associated with
Frontiers in Oncology | Cancer Epidemiology and Prevention May 2013 | Volume 3 | Article 114 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sameer Colorectal cancer genetics
mucinous histotype. Ann. Oncol. 13,
1438–1446.
Behrens, J. (2005). The role of the
Wnt signalling pathway in colorectal
tumorigenesis. Biochem. Soc. Trans.
33, 672–676.
Benatti, P., Gafa, R., Barana, D., Marino,
M., Scarselli, A., Pedroni, M., et al.
(2005). Microsatellite instability and
CRC prognosis. Clin. Cancer Res. 11,
8332–8340.
Boguski, M., and McCormick, F. (1993).
Proteins regulating Ras and its rela-
tives. Nature 366, 643–653.
Bojesen, S. E., and Nordestgaard, B.
G. (2008). The common germline
Arg72Pro polymorphism of p53 and
increased longevity in humans. Cell
Cycle 7, 158–163.
Boland, C. R., Thibodeau, S. N., Hamil-
ton, S. R., Sidransky, D., Eshleman,
J. R., Burt, R. W., et al. (1998).
National Cancer Institute workshop
on microsatellite instability for can-
cer detection and familial predis-
position: development of interna-
tional criteria for the determination
of microsatellite instability in CRC.
Cancer Res. 58, 5248–5257.
Borrensen-Dale, A., Lothe, R. A., Mel-
ing, G. I., Hainut, P., Rognum, T.
O., and Skovlund, E. (1998). TP53
and long-term prognosis in colorec-
tal cancer: mutations in the L3 zinc-
binding domain predict poor sur-
vival. Clin. Cancer Res. 4, 203–210.
Brink, M., Weijenberg, M. P., de Goeij,
A. F., Roemen, G. M., Lentjes, M. H.,
de Bruine, A. P., et al. (2005). Meat
consumption and K-ras mutations
in sporadic colon and rectal cancer
in The Netherlands cohort study. Br.
J. Cancer 92, 1310–1320.
Center, M. M., Jemal, A., Smith, R.
A., and Ward, E. (2009). Worldwide
variations in colorectal cancer. CA
Cancer J. Clin. 59, 366–378.
Chao, C., Zhang, Z.-F., Berthiller, J., Bof-
fetta, P., and Hashibe, M. N. A. D.
(2006). (P)H:quinone oxidoreduc-
tase 1 (NQO1) Pro187Ser polymor-
phism and the risk of lung. Blad-
der, and colorectal cancers: a meta-
analysis.Cancer Epidemiol. Biomark-
ers Prev. 15, 979–987.
Chen, H., Lum, A., Seifried, A.,
Wilkens, L. R., and Marchand,
L. L. (1999). Association of the
NAD(P)H:quinone oxidoreductase
609C3T polymorphism with a
decreased lung cancer risk1. Cancer
Res. 59, 3045–3048.
Chen, J., Röcken, C., Lofton-Day, C.,
Schulz,H. U.,Müller, O.,Kutzner,N.,
et al. (2005). Molecular analysis of
APC promoter methylation and pro-
tein expression in colorectal cancer
metastasis.Carcinogenesis 26, 37–43.
Cicek, M. S., Nock, N. L., Li, L., Conti, D.
V., Casey, G., and Witte, J. S. (2004).
Relationship between methylenete-
trahydrofolate reductase C677T and
A1298C genotypes and haplotypes
and prostate cancer risk and aggres-
siveness. Cancer Epidemiol. Bio-
markers Prev. 13, 1331–1336.
Conlin, A., Smith, G., Carey, F. A.,
Wolf, C. R., and Steele, R. J. (2005).
The prognostic significance of K-ras,
p53, and APC mutations in colorec-
tal carcinoma. Gut 54, 1283–1286.
Costa, S., Pinto, D., Pereira, D.,
Rodrigues, H., Cameselle-Teijeiro, J.,
Medeiros, R., et al. (2008). Impor-
tance of TP53 codon 72 and intron
3 duplication 16bp polymorphisms
in prediction of susceptibility on
breast cancer. BMC Cancer 8:32.
doi:10.1186/1471-2407-8-32
Davies, H., Bignell, G. R., Cox, C.,
Stephens, P., Edkins, S., Clegg, S., et
al. (2002). Mutations of the BRAF
gene in human cancer. Nature 417,
949–954.
Debuire, B., Lemoine, A., and Saffroy,
R. (2002). CTNNB1 (catenin,
beta-1). Atlas Genet. Cytogenet.
Oncol. Haematol. Available at:
http://AtlasGeneticsOncology.org/
Genes/CTNNB1ID71.html
Dolcetti, R.,Viel,A., Doglioni, C., Russo,
A., Guidoboni, M., Capozzi, E., et al.
(1999). High prevalence of activated
intraepithelial cytotoxic T lympho-
cytes and increased neoplastic cell
apoptosis in colorectal carcinomas
with microsatellite instability. Am. J.
Pathol. 154, 1805–1813.
Domingo, E., and Schwartz, S. Jr.
(2004). BRAF. Atlas Genet. Cyto-
genet. Oncol. Haematol. Available at:
http://AtlasGeneticsOncology.org/
Genes/BRAFID828.html
Donovan, S., Shannon, K. M., and Bol-
lag, G. (2002). GTPase activating
poteins: critical regulators of intra-
cellular signaling. BBA Rev. Cancer
1602, 23–45.
Dukes, C. E. (1932). The classification
of cancer of the rectum. J. Pathol.
Bacteriol. 35, 323.
Dumont, P., Leu, J. I., Della Pietra, A. C.
III, George, D. L., and Murphy, M.
(2003). The codon 72 polymorphic
variants of p53 have markedly differ-
ent apoptotic potential. Nat. Genet.
33, 357–365.
Esteller, M., Gonzalez, S., Risques, R. A.,
Marcuello, E., Mangues, R., Germa,
J. R., et al. (2001). RAS and p16
aberrations confer poor prognosis
in human CRC. J. Clin. Oncol. 19,
299–304.
Esteller, M., and Herman, J. G. (2002).
Cancer as an epigenetic disease:
DNA methylation and chromatin
alterations in human tumours. J.
Pathol. 196, 1–7.
Esteller, M., Sparks, A., Toyota, M.,
Sanchez-Cespedes, M., Capella, G.,
Peinado, M. A., et al. (2000). Analysis
of adenomatous polyposis coli pro-
moter hypermethylation in human
cancer. Cancer Res. 60, 4366–4371.
Fearnhead, N. S., Britton, M. P., and
Bodmer, W. F. (2001). The ABC of
APC. Hum.Mol. Genet. 10, 721–733.
Fearon, E. R. (1994). Molecular genetic
studies of the adenoma-carcinoma
sequence. Adv. Intern. Med. 39,
123–147.
Fearon, E. R., and Vogelstein, B. (1990).
A genetic model for colorectal
tumorigenesis. Cell 61, 759–767.
Felley-Bosco, E., Weston, A., Cawley, H.
M., Bennett, W. P., and Harris, C.
C. (1993). Functional studies of a
germ-line polymorphism at codon
47 within the p53 gene. Am. J. Hum.
Genet. 53, 752–759.
Frosst, P., Blom, H. J., Milos, R., Goyette,
P., Sheppard, C. A., Matthews, R. G.,
et al. (1995). A candidate genetic risk
factor for vascular disease: a com-
mon mutation in methylenetetrahy-
drofolate reductase. Nat. Genet. 10,
111–113.
Guengerich, F. P., Kim, D. H., and
Iwasaki, M. (1991). Role of human
cytochrome P450 IIE1 in the oxida-
tion of many low molecular weight
cancer suspects. Chem. Res. Toxicol.
4, 168–179.
Hamelin, P. (1998). APC (adenomatous
polyposis coli). Atlas Genet. Cyto-
genet. Oncol. Haematol. Available at:
http://AtlasGeneticsOncology.org/
Genes/APC118.html
Hardy, R. G., Meltzer, S. T., and
Jankowski, J. A. (2001). “Molecular
basis for risk factors,” inABC of CRC,
eds D. J. Kerr, A. N. Young, and F. D.
R. Hobbs (London: British Medical
Journal Books), 5.
Harris, C. C., and Hollstein, M. (1993).
Clinical implication of the p53
tumor suppressor gene. N. Engl. J.
Med. 329, 1318–1327.
Hayashi, S., Watanabe, J., and Kawa-
jiri, K. (1991). Genetic polymor-
phisms in the 5’-flanking region
change transcriptional regulation of
the human cytochrome P450IIE1
gene. J. Biochem. 110, 559–565.
Hiltunen, M. O., Alhonen, L., Koisti-
naho, J., Myöhänen, S., Kashiwaba,
M., Osakabe, M., et al. (1997).
Hypermethylation of the APC (ade-
nomatous polyposis coli) gene pro-
moter region in human colorec-
tal carcinoma. Int. J. Cancer 70,
644–648.
Hong-Tao, X., Qiang, W., Yang, L., Lian-
He, Y., Shun-Dong, D., Yang, H., et
al. (2007). Overexpression of axin
downregulates TCF-4 and inhibits
the development of lung cancer.
Ann. Surg. Oncol. 14, 3251–3259.
Hsieh, J. S., Lin, S. R., Chang, M. Y.,
Chen, F. M., Lu, C. Y., Huang, T. J.,
et al. (2005). APC. K-ras, and p53
gene mutations in CRC patients: cor-
relation to clinicopathologic features
and postoperative surveillance. Am.
Surg. 71, 336–343.
Ignaszak-Szczepaniak, M., Horst-
Sikorska, W., Sawicka, J., Kaczmarek,
M., and Slomski, R. (2006). The
TP53 codon 72 polymorphism and
predisposition to adrenocortical
cancer in Polish patients. Oncol.
Rep. 16, 65–71.
Ionita-Laza, I., Rogers, A. J., Lange, C.,
Raby, B. A., and Lee, C. (2009).
Genetic association analysis of copy-
number variation (CNV) in human
disease pathogenesis. Genomics 93,
22–26.
Kang, G. H., Lee, S., Kim, J. S., and
Jung, H. Y. (2003). Profile of aber-
rant CpG island methylation along
the multistep pathway of gastric car-
cinogenesis. Lab. Invest. 83, 635–641.
Kerr, D. J., Young, E. M., and Hobbs, F.
D. R. (2001).ABCOf Colorectal Can-
cer. 1st Edn, London: British Medical
Journal
Kharasch, E. D., and Thummel,
K. E. (1993). Identification of
cytochrome P450 2E1 as the pre-
dominant enzyme catalyzing human
liver microsomal defluorination
of sevoflurane, isoflurane, and
methoxyflurane. Anesthesiology 79,
795–807.
Khosrave-far, R., and Der, C. J. (1994).
The ras signal transduction pathway.
Cancer Metastasis Rev. 13, 67–89.
Kono, S., and Chen, K. (2005).
Genetic polymorphisms of meth-
ylenetetrahydrofolate reductase and
colorectal cancer and adenoma.
Cancer Sci. 96, 535–542.
Lammi, L., Arte, S., Somer, M., Jarvi-
nen, H., Lahermo, P., Thesleff, I.,
et al. (2004). Mutations in AXIN2
cause familial tooth agenesis and
predispose to colorectal cancer. Am.
J. Hum. Genet. 74, 1043–1050.
Leu, J. I., Dumont, P., Hafey, M.,
Murphy, M. E., and George, D. L.
(2004). Mitochondrial p53 activates
Bak and causes disruption of a Bak-
Mcl1 complex. Nat. Cell Biol. 6,
443–450.
Levine, A. J., Momand, J., and Finlay,
C. A. (1991). The p53 tumour
suppressor gene. Nature 351,
453–456.
Li, X., Dumont, P., Della, P. A., Shetler,
C., and Murphy, M. E. (2005). The
codon 47 polymorphism in p53
www.frontiersin.org May 2013 | Volume 3 | Article 114 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sameer Colorectal cancer genetics
is functionally significant. J. Biol.
Chem. 280, 24245–24251.
Lind, G. E., Thorstensen, L., Løvig, T.,
Meling, G. I., Hamelin, R., Rognum,
T. O., et al. (2004). A CpG island
hypermethylation profile of primary
colorectal carcinomas and colon
cancer cell lines. Mol. Cancer 3, 28.
Ma, J., Stampfer, M. J., Giovannucci,
E., Artigas, C., Hunter, D. J., Fuchs,
C., et al. (1997). Methylenetetrahy-
drofolate reductase polymorphism,
dietary interactions, and risk of
colorectal cancer. Cancer Res. 57,
1098–1102.
Marin, M. C., Jost, C. A., Brooks, L. A.,
Irwin, M. S., O’Nions, J., Tidy, J. A.,
et al. (2000). A common polymor-
phism acts as an intragenic modi-
fier of mutant p53 behaviour. Nat.
Genet. 25, 47–54.
Massagué, J., Blain, S. W., and Lo, R. S.
(2000). TGF-β signaling in growth
control, cancer and heritable disor-
ders. Cell 103, 295–309.
Miller, R. D., Phillips, M. S., Jo, I.,
Donaldson, M. A., Studebaker, J. F.,
Addleman, N., et al. (2005). High-
density single-nucleotide polymor-
phism maps of the human genome.
Genomics 86, 117–126.
Morita, M., Tabata, S., Tajima, O., Yin,
G., Abe, H., and Kono, S. (2008).
Genetic polymorphisms of CYP2E1
and risk of colorectal adenomas in
the self defense forces health study.
Cancer Epidemiol. Biomarkers Prev.
17, 1800–1807.
Murphy, M. E. (2006). Polymorphic
variants in the p53 pathway. Cell
Death Differ. 13, 916–920.
Nomura, F., Itoga, S., Uchimoto, T.,
Tomonaga, T., Nezu, M., Shimada,
H., et al. (2003). Transcriptional
activity of the tandem repeat poly-
morphism in the 5′-flanking region
of the human CYP2E1 gene.Alcohol.
Clin. Exp. Res. 27, 42S–46S.
O’Brien, M. J., Winawer, S. J., and
Zauber, A. G. (2004). Flat adeno-
mas in the national polyp study: is
there increased risk for high-grade
dysplasia initially or during surveil-
lance?Clin.Gastroenterol.Hepatol. 2,
905–911.
Paula, M. C., and Harold, F. (2002). The
genetics of CRC. Ann. Intern. Med.
137, 603–612.
Pietsch, E. C., Humbey, O., and Mur-
phy, M. E. (2006). Polymorphisms
in the p53 pathway. Oncogene 25,
1602–1611.
Polakis, P. (2000). Wnt signaling and
cancer. Genes Dev. 14, 1837–1851.
Remvikos, Y., Laurent-Puig, P., Salmon,
R. J., Frelat, G., Dutrillaux, B., and
Thomas, G. (1990). Simultaneous
monitoring of p53 protein and DNA
content of colorectal adenocarcino-
mas by flow cytometry. Int. J. Cancer
45, 450–456.
Ross, D. (2004). NQO1. Atlas
Genet. Cytogenet. Oncol.
Haematol. Available at:
http://AtlasGeneticsOncology.
org/Genes/NQO1ID375.html
Roth,S., Johansson,M.,Loukola,A.,Pel-
tomaki, P., Jarvinen, H., Mecklin, J.-
P., et al. (2003). Mutation analysis of
SMAD2, SMAD3, and SMAD4 genes
in hereditary non-polyposis CRC. J.
Cell. Sci. 11, 413–419.
Rowan, A. J., Lamlum, H., Ilyas,
M., Wheeler, J., Straub, J.,
Papadopoulou, A., et al. (2000). APC
mutations in sporadic colorectal
tumors: A mutational “hotspot”
and interdependence of the “two
hits.” Proc. Natl. Acad. Sci. U.S.A.
97, 3352–3357.
Saffroy, R., Lemoine, A., and
Debuire, B. (2005). MTHFR
(5,10-Methylenetetrahydrofolate
reductase). Atlas Genet Cytogenet
Oncol Haematol. Available at: http://
AtlasGeneticsOncology.org/Genes/
MTHFRID41448ch1p36.html
Saffroy, R., Lemoine, A., and Debuire,
B. (2004). SMAD4 (mothers
against decapentaplegic homolog 4
(Drosophila)). Atlas Genet. Cyto-
genet. Oncol. Haematol. Available at:
http://AtlasGeneticsOncology.org/
Genes/SMAD4ID371.html
Savas, S., and Liu, G. (2009). Studying
genetic variations in cancer progno-
sis (and risk): a primer for clinicians.
Oncologist 14, 657–666.
Sayar, N., and Banerjee, S. (2007).
Colon: Colorectal adenocarcinoma.
Atlas Genet Cytogenet. Oncol.
Haematol. Available at: http://Atlas
GeneticsOncology.org/Tumors/
colon5006.html
Schubbert, S., Shannon, K., and Bollag,
G. (2007). Hyperactive Ras in devel-
opmental disorders and Cancer.Nat.
Rev. Cancer 7, 295–308.
Schutte, M., Hruban, R. H., Hedrick, L.,
Cho, K. R., Nadasdy, G. M., Wein-
stein, C. L., et al. (1996). DPC4 gene
in various tumor types. Cancer Res.
56, 2527–2530.
Shi, Y. (2001). Structural insights on
Smad function in TGF-β signaling.
Bioessays 23, 223–232.
Siegel, D., Gustafson, D. L., Dehn,
D. L., Han, J. Y., Boonchoong,
P., Berliner, L. J., et al. (2004).
NAD(P)H:quinone oxidoreductase
1: role as a superoxide scavenger.
Mol. Pharmacol. 65, 1238–1247.
Soussi, T., and Beroud, C. (2001).
Assessing TP53 status in human
tumours to evaluate clinical out-
come. Nat. Rev. Cancer 1, 233–240.
Thomas, M., Kalita, A., Labrecque,
S., Pim, D., Banks, L., and Mat-
lashewski, G. (1999). Two polymor-
phic variants of wild-type p53 differ
biochemically and biologically. Mol.
Cell. Biol. 19, 1092–1100.
Tirnauer, J. (2005). APC (adenomatous
polyposis coli). Atlas Genet. Cyto-
genet. Oncol. Haematol. Available at:
http://AtlasGeneticsOncology.org/
Genes/APC118.html
Toyama, T., Zhang, Z., Nishio, M., Ham-
aguchi, M., Kondo, N., Iwase, H.,
et al. (2007). Association of TP53
codon 72 polymorphism and the
outcome of adjuvant therapy in
breast cancer patients. Breast Cancer
Res. 9, R34.
Tsuchiya, T., Tamura, G., Sato, K.,
Endoh, Y., Sakata, K., Jin, Z., et
al. (2000). Distinct methylation
patterns of two APC gene promoters
in normal and cancerous gastric
epithelia. Oncogene 19, 3642–3646.
Ulusoy, G., Arinç, E., and Adali, O.
(2007). Genotype and allele frequen-
cies of polymorphic CYP2E1 in the
Turkish population. Arch. Toxicol.
81, 711–718.
Vainio, H., and Miller, A. B. (2003). Pri-
mary and secondary prevention in
CRC. Acta Oncol. 42, 809–815.
Virmani, A. K., Rathi, A., Sathya-
narayana, U. G., Padar, A., Huang,
C. X., Cunnigham, H. T., et al.
(2001). Aberrant methylation of the
adenomatous polyposis coli (APC)
gene promoter 1A in breast and
lung carcinomas. Clin. Cancer Res.
7, 1998–2004.
Vogelstein, B., Fearon, E. R., Hamilton,
S. R., Kern, S. E., Preisinger, A. C.,
Leppert, M., et al. (1988). Genetic
alterations during colorectal-tumor
development. N. Engl. J. Med. 319,
525–532.
Wagner, C. (1995). “Biochemical role
of folate in cellular metabolism,” in
Folate in Health and Disease, ed. L. B.
Bailey (New York: Marcel Dekker),
23–42.
Wan, P. T., Garnett, M. J., Roe, S. M.,
Lee, S., Niculescu-Duvaz, D., Good,
V. M., et al. (2004). Mechanism of
activation of the RAF-ERK signaling
pathway by oncogenic mutations of
B-RAF. Cell 116, 855–867.
Wang, Y., Yang, H., Li, L., Wang, H.,
Zhang, C.,Yin, G., et al. (2010). Asso-
ciation between CYP2E1 genetic
polymorphisms and lung cancer
risk: a meta-analysis. Eur. J. Cancer
46, 758–764.
Watzinger, F., and Lion, T. (1999).
RAS family. Atlas Genet. Cytogenet.
Oncol. Haematol. Available at:
http://AtlasGeneticsOncology.org/
Deep/Ras.html
Whibley, C., Pharoah, P. D. P., and
Hollstein, M. (2009). p53 Polymor-
phisms: cancer implications. Nat.
Rev. Cancer 9, 95–107.
Winski, S. L., Koutalos, Y., Bentley, D.
L., and Ross, D. (2002). Subcellular
localization of NAD(P)H: quinone
oxidoreductase 1 inhuman cancer
cells. Cancer Res. 62, 1420–1424.
Woodford-Richens, K. L., Rowan, A. J.,
Poulsom, R., Bevan, S., Salovaara,
R., Aaltonen, L. A., et al. (2001).
Comprehensive analysis of SMAD4
mutations and protein expression
in juvenile polyposis: evidence for
a distinct genetic pathway and
polyp morphology in SMAD4 muta-
tion carriers. Am. J. Pathol. 159,
1293–1300.
Wrana, J. L. (2000). Regulation of Smad
activity. Cell 100, 189–192.
Zare, M., Jazii, F. R., Alivand, M. R.,
Nasseri, N. K., Malekzadeh, R., and
Yazdanbod, M. (2009). Qualitative
analysis of adenomatous polypo-
sis coli promoter: Hypermethyla-
tion, engagement and effects on sur-
vival of patients with esophageal
cancer in a high risk region of
the world, a potential molecu-
lar marker. BMC Cancer 9:24.
doi:10.1186/1471-2407-9-24
Zauber, A. G., O’Brien, M. J., and
Winawer, S. J. (2002). On finding flat
adenomas: is the search worth the
gain?Gastroenterology 122, 839–840.
Zhou, G. W., Hu, J., and Li, Q.
(2010). CYP2E1 Pst/Rsa polymor-
phism and colorectal cancer risk:
a meta-analysis. World J. Gastroen-
terol. 16, 2949–2953.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 16 October 2012; accepted: 25
April 2013; published online: 13 May
2013.
Citation: Sameer AS (2013) Colorectal
Cancer: Molecular Mutations and Poly-
morphisms. Front. Oncol. 3:114. doi:
10.3389/fonc.2013.00114
This article was submitted to Frontiers in
Cancer Epidemiology and Prevention, a
specialty of Frontiers in Oncology.
Copyright © 2013 Sameer. This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tion License, which permits use, distrib-
ution and reproduction in other forums,
provided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
Frontiers in Oncology | Cancer Epidemiology and Prevention May 2013 | Volume 3 | Article 114 | 8
